{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"45"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"10"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"45"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"10"}],"units":"Participants"}],"description":"An adverse event was defined as any untoward medical occurrence in a participant administered study treatment and did not necessarily have a causal relationship with this treatment. An adverse event could be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that was temporally associated with the use of the study treatment was also an adverse event.","groups":[{"description":"Participants in Part 1 with refractory or relapsed and refractory multiple myeloma (rrMM) received pembrolizumab 2 mg/kg once every 2 weeks (Q2W) (Days 1 and 15) in combination with lenalidomide 25 mg (Days 1-21) and dexamethasone 40 mg once weekly (Q1W) during Cycle 1 (28-day cycle).","id":"OG000","title":"Part 1:Pembro 2mg/kg+Len 25mg+Dex 40 mg"},{"description":"Participants in Part 1 with refractory or relapsed and refractory multiple myeloma (rrMM) received pembrolizumab 2 mg/kg Q2W (Days 1 and 15) in combination with lenalidomide 10 mg (Days 1-21) and dexamethasone 40 mg Q1W during Cycle 1 (28-day cycle).","id":"OG001","title":"Part 1:Pembro 2mg/kg+Len 10 mg+Dex 40 mg"},{"description":"Participants in Part 2 with refractory or relapsed and refractory multiple myeloma (rrMM) received pembrolizumab 200 mg Q2W (Days 1 and 15) in combination with lenalidomide 25 mg (Days 1-21) and dexamethasone 40 mg Q1W during Cycle 1 (28-day cycle).","id":"OG002","title":"Part 2:Pembro 200 mg+Len 25 mg+Dex 40 mg"},{"description":"Participants in Part 2 with refractory or relapsed and refractory multiple myeloma (rrMM) received pembrolizumab 200 mg Q2W (Days 1 and 15) in combination with lenalidomide 25 mg (Days 1-21) and dexamethasone 20 mg Q1W during Cycle 1 (28-day cycle).","id":"OG003","title":"Part 2:Pembro 200 mg+Len 25 mg+Dex 20 mg"},{"description":"Participants in Part 2 with refractory or relapsed and refractory multiple myeloma (rrMM) received pembrolizumab 200 mg Q2W (Days 1 and 15) in combination with lenalidomide 10 mg (Days 1-21) and dexamethasone 40 mg Q1W during Cycle 1 (28-day cycle).","id":"OG004","title":"Part 2:Pembro 200 mg+Len 10 mg+Dex 40 mg"},{"description":"Participants in Part 3 with refractory or relapsed and refractory multiple myeloma (rrMM) received pembrolizumab 200 mg Q2W (Days 1 and 15) in combination with lenalidomide 25 mg (Days 1-21) and dexamethasone 40 mg Q1W during each 28-day cycle.","id":"OG005","title":"Part 3:Pembro 200 mg+Len 25 mg+Dex 40 mg"},{"description":"Participants in Part 3 with refractory or relapsed and refractory multiple myeloma (rrMM) received pembrolizumab 200 mg Q2W (Days 1 and 15) in combination with lenalidomide 25 mg (Days 1-21) and dexamethasone 20 mg Q1W during each 28-day cycle.","id":"OG006","title":"Part 3:Pembro 200 mg+Len 25 mg+Dex 20 mg"},{"description":"Participants in Part 3 with relapsed or refractory multiple myeloma (rMM) received pembrolizumab 200 mg Q3W in combination with carfilzomib 56 mg/m\\^2 (Days 1, 2, 8, 9, 15, 16) and dexamethasone 20 mg (Days 1, 2, 8, 9, 15, 16, 22, 23) during each 28-day cycle.","id":"OG007","title":"Part 3:Pembro 200 mg+Carf 56 mg/m^2 +Dex 20 mg"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All participants who received ≥1 dose of study treatment.","reportingStatus":"POSTED","timeFrame":"Up to approximately 72.7 months","title":"Number of Participants Who Experienced One or More Adverse Events (AEs)","type":"PRIMARY","unitOfMeasure":"Participants"}